Clinical trial
Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and…
NCT00190749 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00190749 |
|---|---|
| Title | Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder |
| Official title | Insulin Sensitivity in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine and Risperidone |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder |
| Intervention type | Drug |
| Interventions | olanzapine, risperidone |
| Enrollment | 130 |
| Start date | Oct 1, 2003 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Sep 19, 2005 |
| Last update posted | May 4, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: